ASO Visual Abstract: Resectable Pancreatic Cancer with CA19-9 > 500 U/mL-A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy.
作者信息
Omiya Kojiro, Oba Atsushi, Sugiura Kota, Maekawa Aya, Mie Takafumi, Kobayashi Kosuke, Ono Yoshihiro, Sasaki Takashi, Ozaka Masato, Sasahira Naoki, Ito Hiromichi, Inoue Yosuke, Takahashi Yu
机构信息
Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan.
出版信息
Ann Surg Oncol. 2025 Aug;32(8):5442-5443. doi: 10.1245/s10434-025-17562-9.
PMID:40468131
Abstract
摘要
相似文献
1
ASO Visual Abstract: Resectable Pancreatic Cancer with CA19-9 > 500 U/mL-A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy.ASO可视化摘要：CA19-9>500 U/mL的可切除胰腺癌——强化新辅助化疗生存获益的生物学指标
Ann Surg Oncol. 2025 Aug;32(8):5442-5443. doi: 10.1245/s10434-025-17562-9.
引用本文的文献
1
[Stereotactic radiotherapy in functionally inoperable but technically resectable pancreatic cancer].[立体定向放射治疗在功能上无法手术但技术上可切除的胰腺癌中的应用]
Strahlenther Onkol. 2025 Aug;201(8):857-858. doi: 10.1007/s00066-025-02429-5. Epub 2025 Jun 17.
2
ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy.ASO作者反思：优化可切除胰腺癌的治疗：CA19-9>500 U/mL作为新辅助治疗的生物学指标
Ann Surg Oncol. 2025 May 21. doi: 10.1245/s10434-025-17458-8.
Zotero 插件